Stock Rating Downgrade The Value Trend Rating for Cross Country Healthcare Inc (NASDAQ: CCRN) weakened in recent days from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are […]
On 3/1/24, Catalyst Biosciences Inc (NASDAQ: CBIO) stock enjoyed a major increase of 13.5%, closing at $20.58. However, below average trading volume at 73% of normal accompanied the advance. The stock has been exceptionally strong […]
On 3/4/24, Zevra Therapeutics Inc (NASDAQ: ZVRA) stock suffered a major decline of -12.1%, closing at $6.22. Moreover, trading volume in this decline was exceptionally high at 270% of normal. Relative to the market the […]
Smith-Midland Corp (NASDAQ: SMID) stock closed at $35.94 on 3/4/24 after a major decline of -18.8%. Moreover, trading volume in this decline was above average at 142% of normal. The stock has declined -19.6% during […]
Voyager Therapeutics Inc (NASDAQ: VYGR) stock enjoyed a major increase of 13.5% on 3/1/24. The shares closed at $9.44. Moreover, trading volume in this advance was above average at 125% of normal. The stock has […]
Stock Rating Upgrade The Value Trend Rating for Viper Energy Partners LP (NASDAQ: VNOM) improved recently from C to B reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in […]
Extremely important negative changes in investment behavior have recently occurred for JAKKS Pacific Inc (NASDAQ: JAKK): the stock’s recent price decline challenged its longer term uptrend, its shorter term price trend turned down, the stock […]
On 3/4/24, G III Apparel Group Ltd (NASDAQ: GIII) stock suffered a major decline of -10.6%, closing at $29.73. Moreover, this decline was accompanied by exceptionally high trading volume at 236% of normal. Relative to […]
On 3/4/24, BGC Partners Inc (NASDAQ: BGCP) stock enjoyed a major increase of 14.6%, closing at $8.14. Moreover, trading volume in this advance was exceptionally high at 826% of normal. Relative to the market the […]
Stock Rating Upgrade The Value Trend Rating for OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) improved in the last week from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research